Repetitive Transcranial Magnetic Stimulation (rTMS) for Schizophrenia
This trial will use magnetic pulses to try and lessen symptoms of schizophrenia, specifically auditory hallucinations.
2 Primary · 7 Secondary · Reporting Duration: Up to 4 weeks.
1 Treatment Group
Individualized magnetic resonance imaging (MRI) guided rTMS
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: Repetitive Transcranial Magnetic Stimulation (rTMS) · No Placebo Group · N/A
Who is running the clinical trial?
Age 22 - 55 · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|New York State Psychiatric Institute||100.0%|
What portion of applicants met pre-screening criteria?
Frequently Asked Questions
How many participants are actively engaged in this research endeavor?
"Confirmed. According to the information available on clinicaltrials.gov, this medical experiment is actively enrolling participants since its initial posting on August 1st 2022 and last update of August 2nd 2022. A total of 12 patients are needed from a single location." - Anonymous Online Contributor
Does the recruitment for this research include individuals older than twenty?
"According to the specified inclusion criteria, only individuals aged between 22 and 55 can join this clinical trial. Those younger than 18 are limited to 47 studies while there is a greater assortment of options for those over 65 with 169 available." - Anonymous Online Contributor
Are there open slots to take part in the clinical research presently?
"Affirmative, the information found on clinicaltrials.gov shows that this study is currently recruiting participants. The trial was initially posted on August 1st 2022 and last updated a single day later, with 12 patients sought from one site." - Anonymous Online Contributor
What objectives is the research team looking to accomplish with this clinical trial?
"The principle objective of this experimental trial, to be assessed over a two-week period, is the total number of treatment emergent adverse events. Secondary objectives include gauging changes in Cardiff Anomalous Perceptions Scale (CAPS), Psychotic Symptom Rating Scale (PSYRATS) and Scale for the Assessment of Positive Symptoms (SAPS). CAPS scores range from 0-32 with higher numbers indicating more perceptual anomalies; PSYRATS consists of 17 items rated from none to severe on auditory hallucinations and delusions; SAPS includes 34 items that measure positive symptoms related to schizophrenia each given an intensity score between 0-5." - Anonymous Online Contributor
What are the ideal characteristics of a participant for this research effort?
"Candidates aged 22 to 55 with a schizophrenia diagnosis are eligible for this clinical trial. A ceiling of 12 participants exists for the experiment." - Anonymous Online Contributor